Search

Your search keyword '"MESH: Dermatologic Agents"' showing total 11 results
Start Over Descriptor "MESH: Dermatologic Agents"
11 results on '"MESH: Dermatologic Agents"'

1. Secukinumab Therapy for Netherton Syndrome

Author

Corinne Brunner, Barbara Meier-Schiesser, Nicole Knöpfel, Claire Barbieux, Mathilde Bonnet des Claustres, Alain Hovnanian, Davide Donghi, Agnes Schwieger-Briel, Lisa Weibel, Isabelle Luchsinger, Martin Theiler, Michael Buettcher, University of Zurich, Weibel, Lisa, Université Paris Cité, Equipe HAL, Différentiation et rôle pathogénique des lymphocytes T auxiliaires folliculaires dans la marche atopique - - Tfh-Atopy2017 - ANR-17-CE14-0025 - AAPG2017 - VALID, Développement d'une nouvelle biothérapie ciblant les mécanismes inflammatoires du syndrome de Netherton - - TARGET-NS2019 - ANR-19-CE17-0017 - AAPG2019 - VALID, University Children’s Hospital Zurich, Genetic skin diseases : from disease mechanism to therapies (Equipe Inserm U1163), Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Université Paris Cité (UPCité), Bellinzona Regional Hospital [Bellinzona], Children’s Hospital Lucerne, Partenaires INRAE, University hospital of Zurich [Zurich], Service de génétique moléculaire [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), This study was supported by the ANR-17-CE14-0025-03 Tfh-Atopy project and ANR-19-CE17-0017-01 TARGET-NS (Drs Hovnanian and Barbieux) funded by the French National Research Agency and Imagine cross-laboratory project (Dr Bonnet des Claustres) funded by the Imagine Institute., ANR-17-CE14-0025,Tfh-Atopy,Différentiation et rôle pathogénique des lymphocytes T auxiliaires folliculaires dans la marche atopique(2017), and ANR-19-CE17-0017,TARGET-NS,Développement d'une nouvelle biothérapie ciblant les mécanismes inflammatoires du syndrome de Netherton(2019)

Subjects
Compassionate Use Trials, Male, Erythema, MESH: Interleukin-17, Severity of Illness Index, MESH: Netherton Syndrome, 030207 dermatology & venereal diseases, 0302 clinical medicine, MESH: Child, Child, Skin, MESH: Compassionate Use Trials, Interleukin-17, Dermatology Life Quality Index, Phenotype, MESH: Young Adult, 030220 oncology & carcinogenesis, Female, Interleukin 17, medicine.symptom, Adult, medicine.medical_specialty, 610 Medicine & health, Dermatology, MESH: Onychomycosis, MESH: Phenotype, Antibodies, Monoclonal, Humanized, 2708 Dermatology, Young Adult, 03 medical and health sciences, MESH: Skin, MESH: Severity of Illness Index, Ichthyosis linearis circumflexa, Onychomycosis, medicine, Humans, Netherton syndrome, 10220 Clinic for Surgery, MESH: Pruritus, Adverse effect, MESH: Humans, Chemokine CCL20, business.industry, Pruritus, MESH: Quality of Life, MESH: Adult, [SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology, MESH: Chemokine CCL20, medicine.disease, MESH: Male, MESH: Dermatologic Agents, MESH: Antibodies, Monoclonal, Humanized, Netherton Syndrome, Quality of Life, Secukinumab, Dermatologic Agents, business, MESH: Female, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, Case series
Abstract

International audience; ImportanceNetherton syndrome (NS) is a rare, severe genetic disorder of cornification with high morbidity. Treatment for NS has been notoriously difficult. Recent studies showed an upregulated helper T cell (TH) 17/interleukin 23 (IL-23) pathway in NS, suggesting the possibility of treatment strategies that target IL-17.ObjectiveTo evaluate the clinical response of NS to treatment with the IL-17 antagonist secukinumab.Design, Setting, and ParticipantsThis case series study reports the experience of compassionate use therapy with secukinumab in 4 patients with severe NS, including 2 children, from December 1, 2018, to December 1, 2019, with 3 patients still undergoing treatment at the time of final analysis. Data were analyzed from December 1, 2018, to December 1, 2019.Main Outcomes and MeasuresExpression of IL-17 in the skin was evaluated by immunohistochemical analysis, and serum cytokine concentrations were measured using a commercially available assay. Treatment response was assessed using the Ichthyosis Area and Severity Index (IASI) total score, including measures of erythema and scaling, the Dermatology Life Quality Index (DLQI), and the 5-D itch scale.ResultsIn all 4 patients (age range, 9-27 years; 3 male and 1 female), immunostaining with an IL-17A antibody showed an increased number of positive cells in lesional skin. Cytokine assessment in serum samples revealed increased levels of CCL20. Treatment duration with secukinumab was 3 to 12 months at the time of this report. After 3 months of therapy, IASI scores were reduced by 44% to 88%, DLQI scores were reduced by 40% to 76%, and 5-D itch scale scores were reduced by 27% to 62%. This outcome was sustained at the 6-month follow-up. Two patients with an erythrodermic phenotype showed marked improvement of all parameters. A refractory palmoplantar eczematous eruption occurred in 2 patients, and a candidal nail infection developed in 2 patients. No severe adverse events were reported.Conclusions and RelevanceThis initial case series reporting the use of anti–IL-17 therapy in NS demonstrated marked cutaneous improvement, particularly in 2 pediatric patients with erythrodermic phenotypes. Further studies are needed to evaluate the long-term benefit of this potential treatment modality.

Published
2020

2. Clinical, biometric and structural evaluation of the long-term effects of a topical treatment with ascorbic acid and madecassoside in photoaged human skin

Author

Pierre Creidi, Marek Haftek, Sophie Mac-Mary, Philippe Humbert, Marie-Aude Le Bitoux, Sophie Seité, André Rougier, Fonctions Normales et Pathologiques de la Barrière Cutanée [Hôpital Edouard Herriot - HCL], Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), La Roche Posay Pharmaceutical Laboratories, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Saas, Philippe, Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)

Subjects
Pathology, MESH: Elastic Tissue, Human skin, Ascorbic Acid, Biochemistry, 030207 dermatology & venereal diseases, chemistry.chemical_compound, 0302 clinical medicine, Skin Physiological Phenomena, MESH: Ascorbic Acid, MESH: Double-Blind Method, MESH: Biometry, MESH: Treatment Outcome, Skin, 0303 health sciences, MESH: Middle Aged, integumentary system, Dermis, Middle Aged, MESH: Administration, Cutaneous, 3. Good health, Treatment Outcome, medicine.anatomical_structure, MESH: Skin Physiological Phenomena, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, Elastic fiber, Vitamin, medicine.medical_specialty, Biometry, [SDV.IMM] Life Sciences [q-bio]/Immunology, MESH: Microscopy, Electron, Dermatology, Administration, Cutaneous, 03 medical and health sciences, MESH: Skin, Double-Blind Method, medicine, Humans, Molecular Biology, 030304 developmental biology, MESH: Humans, business.industry, MESH: Triterpenes, Papillary dermis, MESH: Dermis, Elastic Tissue, Ascorbic acid, Elasticity, Triterpenes, Skin Aging, Microscopy, Electron, MESH: Dermatologic Agents, chemistry, Ageing, MESH: Skin Aging, MESH: Elasticity, Dermatologic Agents, Epidermis, business, MESH: Female
Abstract

International audience; Skin ageing is a complex process determined by the genetic endowment of individual and environmental factors, such as sun exposure. The effects of skin ageing are mostly encountered in the superficial dermis and in the epidermis. We have previously demonstrated in vivo the beneficial effect of a topically applied formula of 5% vitamin C in the treatment of skin ageing. Another active compound, madecassoside extracted from Centella asiatica, known to induce collagen expression and/or to modulate inflammatory mediators, might thus prevent and correct some signs of ageing. A randomized double-blind study was carried out on photoaged skin of 20 female volunteers to investigate the effects of topically applied 5% vitamin C and 0.1% madecassoside on the clinical, biophysical and structural skin properties. After 6 months of treatment, we observed a significant improvement of the clinical score for deep and superficial wrinkles, suppleness, firmness, roughness and skin hydration. These results were corroborated by measurements of skin elasticity and semi-quantitative histological assessment of the elastic fibre network in the papillary dermis. Two-thirds of the subjects showed an improvement. The re-appearance of a normally structured elastic fibre network was observed. Our results revealed a functional and structural remodelling of chronically sun-damaged skin.

Published
2008

3. Cerebral Ischemia Probably Related to Isotretinoin

Author

Francisco Macian-Montoro, Jean-Michel Vallat, Louis Merle, Marie-Laure Laroche, Service de Pharmacologie, toxicologie et pharmacovigilance [CHU Limoges], CHU Limoges, Service de Neurologie [CHU Limoges], and Université de Limoges (UNILIM)

Subjects
Adult, Male, medicine.medical_specialty, MESH: Heparin, medicine.drug_class, Ischemia, 030204 cardiovascular system & hematology, Brain Ischemia, Central nervous system disease, Brain ischemia, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, MESH: Isotretinoin, medicine, Humans, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, Pharmacology (medical), Retinoid, MESH: Aspirin, Isotretinoin, skin and connective tissue diseases, Acne, MESH: Humans, Aspirin, Heparin, business.industry, Vascular disease, MESH: Brain Ischemia, MESH: Adult, Dipyridamole, medicine.disease, MESH: Male, Facial paralysis, 3. Good health, Surgery, MESH: Dermatologic Agents, MESH: Platelet Aggregation Inhibitors, Anesthesia, MESH: Dipyridamole, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Dermatologic Agents, business, Platelet Aggregation Inhibitors, medicine.drug
Abstract

OBJECTIVE: To report a case of cerebral ischemia in a patient receiving oral isotretinoin for severe acne. CASE SUMMARY: A 30-year-old right-handed man was admitted for left facial paralysis and dysarthria. He had received oral isotretinoin 45 mg/day for 3 months for treatment of severe acne. A cerebral computed tomography scan showed hypodensity in the right middle cerebral territory corresponding to cerebral ischemia. The patient reported having experienced a similar episode 7 years before, after 3 months' treatment with oral isotretinoin. No risk factors were identified. Isotretinoin was discontinued on admission and the disorders resolved. DISCUSSION: Our patient did not present thrombotic risk factors and was not being treated with any drug other than isotretinoin; however, he developed 2 episodes of cerebral ischemia following 2 episodes of oral isotretinoin treatment. According to the Naranjo probability scale, the relationship of cerebral ischemia to administration of isotretinoin was probable. Other reports of thrombotic accidents, as well as some cases of hemorrhage in patients receiving isotretinoin, have been published. This drug seems to act on the coagulation process by a still unexplained mechanism. CONCLUSIONS: Given that isotretinoin is a treatment prescribed most frequently for adolescents and young adults and that cerebral ischemia can produce serious handicaps, an evaluation of vascular risk should be made prior to treatment with this drug.

Published
2007

4. Sequential therapy in plaque psoriasis using the ' Hit and Run ' approach: infliximab followed by efalizumab

Author

Penz, Séverine, Pelletier, Fabien, Riou-Gotta, Marie Odile, Puzenat, Eve, Levang, Julien, Mermet, Isabelle, Humbert, Philippe, Aubin, François, Département de dermatologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques-Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
MESH : Feasibility Studies, MESH : Psoriasis, MESH : Male, MESH : Drug Administration Schedule, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Treatment Outcome, MESH: Drug Administration Schedule, MESH: Antibodies, Monoclonal, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH : Female, MESH : Middle Aged, ComputingMilieux_MISCELLANEOUS, MESH: Treatment Outcome, MESH: Psoriasis, MESH: Humans, MESH: Middle Aged, MESH : Drug Therapy, Combination, MESH : Humans, MESH: Adult, MESH : Adult, MESH: Male, MESH: Drug Therapy, Combination, MESH: Dermatologic Agents, MESH : Dermatologic Agents, MESH : Antibodies, Monoclonal, MESH: Feasibility Studies, MESH: Female
Abstract

International audience

Published
2012

5. PNPLA1 mutations cause autosomal recessive congenital ichthyosis in golden retriever dogs and humans

Author

Anais Grall, Céline Derbois, Matthieu Le Gallo, Ingrid Hausser, Laetitia Lagoutte, Sébastien Küry, Judith Fischer, Catherine André, Emmanuelle Bourrat, Emmanuel Bensignor, Sandrine Planchais, Franz P.W. Radner, Éric Guaguère, Francis Galibert, Rudolf Zechner, Susanne Grond, Jacques Fontaine, Robert Zimmermann, Gwang-Jin Kim, Mark Lathrop, Frédérique Degorce-Rubiales, Anne Thomas, Didier Pin, Christophe Hitte, Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Clinique Vétérinaire Saint Bernard, Institute of Molecular Biosciences, Karl-Franzens-Universität Graz, Service de dermatologie [Paris], Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Department of dermatology, University clinic Heidelberg, Electron Microscopy Core Facility, Universität Heidelberg [Heidelberg], Centre National de Génotypage (CNG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut de Génomique d'Evry (IG), Institut de Biologie François JACOB (JACOB), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Institute for Human Genetics, University Clinic Freiburg, Faculty for Biology, University of Freiburg [Freiburg], Laboratoire d'Anatomie Pathologique Vétérinaire du Sud-Ouest, Animal Genetics Laboratory, Antagene, Service d'ORL et de Chirurgie Cervicofaciale, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Clinique Vétérinaire de la Boulais, Clinique vétérinaire, Clinique vétérinaire, Bruxelles, Interactions Cellules Environnement - UR (ICE), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS), Centre d'Etude du Polymorphisme Humain (CEPH), Université Paris Diderot - Paris 7 (UPD7)-Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Fondation Jean Dausset, Zentrum für Biosystemanalyse, Albert-Ludwigs-Universität Freiburg, This study was supported by CNRS, the European Commission (FP7-LUPA, GA-201370). R. Zechner and R. Zimmermann were supported by the FWF F30 SFB Lipotox, Z136 Wittgenstein, the GEN-AU project GOLD by the Austrian Ministry of Science and Research and FFG. I.H. was supported by the NIRK Network (German BMBF 01GM0904)., European Project: 201370,EC:FP7:HEALTH,FP7-HEALTH-2007-A,LUPA(2008), Institut de Génétique et Développement de Rennes ( IGDR ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Centre National de la Recherche Scientifique ( CNRS ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Assistance publique - Hôpitaux de Paris (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]-Université Paris Diderot - Paris 7 ( UPD7 ), Centre National de Génotypage ( CNG ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ), Institut de Génomique d'Evry ( IG ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Saclay, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -CHU Trousseau [APHP], Unité de Dermatologie, VetAgro Sup ( VAS ), Centre d'Etude du Polymorphisme Humain ( CEPH ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut Universitaire d'Hématologie ( IUH ), Université Paris Diderot - Paris 7 ( UPD7 ) -Fondation Jean Dausset, European Project : 201370,EC:FP7:HEALTH,FP7-HEALTH-2007-A,LUPA ( 2008 ), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Universität Heidelberg [Heidelberg] = Heidelberg University, Université Paris-Saclay-Institut de Biologie François JACOB (JACOB), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), De Villemeur, Hervé, and Unravelling the molecular basis of common complex human disorders using the dog as a model system - LUPA - - EC:FP7:HEALTH2008-01-01 - 2012-06-30 - 201370 - VALID

Subjects
Male, MESH : Molecular Sequence Data, [SDV.GEN] Life Sciences [q-bio]/Genetics, MESH: Base Sequence, medicine.disease_cause, 0403 veterinary science, MESH: Dogs, MESH: INDEL Mutation, MESH: Lipase, MESH : Dogs, INDEL Mutation, Congenital ichthyosis, Missense mutation, MESH : Female, MESH: Animals, MESH: Codon, Nonsense, Cells, Cultured, Skin, Genetics, 0303 health sciences, Mutation, 04 agricultural and veterinary sciences, Lamellar ichthyosis, MESH : Adult, MESH : Lipase, MESH : Dermatologic Agents, MESH : Codon, Nonsense, MESH: Ichthyosis, Lamellar, Codon, Nonsense, Female, MESH : Genome-Wide Association Study, MESH: Cells, Cultured, Adult, 040301 veterinary sciences, MESH : Male, Nonsense mutation, Molecular Sequence Data, Mutation, Missense, ALOX12B, Golden Retriever, Genes, Recessive, MESH: Nitrendipine, Biology, 03 medical and health sciences, Dogs, MESH: Skin, MESH : Cells, Cultured, medicine, MESH : Skin, Animals, Humans, Indel, MESH : INDEL Mutation, MESH: Genes, Recessive, 030304 developmental biology, MESH: Mutation, Missense, [SDV.GEN]Life Sciences [q-bio]/Genetics, MESH: Humans, MESH: Molecular Sequence Data, Base Sequence, Nitrendipine, MESH : Humans, MESH : Ichthyosis, Lamellar, MESH : Genes, Recessive, MESH: Adult, Lipase, [SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology, medicine.disease, MESH : Nitrendipine, MESH: Male, MESH: Dermatologic Agents, MESH: Genome-Wide Association Study, MESH : Base Sequence, MESH : Animals, Dermatologic Agents, [ SDV.GEN ] Life Sciences [q-bio]/Genetics, [ SDV.MHEP.DERM ] Life Sciences [q-bio]/Human health and pathology/Dermatology, MESH: Female, MESH : Mutation, Missense, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, Ichthyosis, Lamellar, Genome-Wide Association Study
Abstract

International audience; Ichthyoses comprise a heterogeneous group of genodermatoses characterized by abnormal desquamation over the whole body, for which the genetic causes of several human forms remain unknown. We used a spontaneous dog model in the golden retriever breed, which is affected by a lamellar ichthyosis resembling human autosomal recessive congenital ichthyoses (ARCI), to carry out a genome-wide association study. We identified a homozygous insertion-deletion (indel) mutation in PNPLA1 that leads to a premature stop codon in all affected golden retriever dogs. We subsequently found one missense and one nonsense mutation in the catalytic domain of human PNPLA1 in six individuals with ARCI from two families. Further experiments highlighted the importance of PNPLA1 in the formation of the epidermal lipid barrier. This study identifies a new gene involved in human ichthyoses and provides insights into the localization and function of this yet uncharacterized member of the PNPLA protein family.

Published
2011

6. How pharmacogenomics of biological response modifiers will influence clinical response and toxicity in dermatology

Author

Dalle, Stéphane, Thomas, Luc, Shear, Neil H, Equipe 14, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Service de Dermatologie, Centre Hospitalier Sud, Hospices Civils, Lyon

Subjects
MESH: Pharmacogenetics, MESH: Piperazines, Drug Resistance, MESH: Skin Diseases, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Receptor, Epidermal Growth Factor, MESH: Receptors, IgG, Skin Diseases, Piperazines, Antibodies, Monoclonal, Murine-Derived, MESH: Polymorphism, Genetic, Humans, Immunologic Factors, Precision Medicine, MESH: Individualized Medicine, MESH: Humans, Polymorphism, Genetic, Tumor Necrosis Factor-alpha, MESH: Immunologic Factors, Receptors, IgG, ErbB Receptors, MESH: Dermatologic Agents, Pyrimidines, MESH: Antibodies, Monoclonal, Murine-Derived, Pharmacogenetics, MESH: Tumor Necrosis Factor-alpha, MESH: Pyrimidines, Benzamides, MESH: Drug Resistance, Imatinib Mesylate, Dermatologic Agents, Rituximab
Abstract

International audience; Biological response modifiers (BRMs) have dramatically changed therapeutic approaches in dermatology. Pharmacogenomic studies are increasingly integral to the early development phases of targeted therapies. The first evidence supporting the impact that genetic background has on responses to BRMs was from rituximab, where the clinical response was correlated with Fc-gamma receptor gene polymorphisms. Later, many studies were done to investigate the impact of gene polymorphism on the mechanism of action of BRMs. Growing evidence supports the view that both efficacy and toxicity of BRMs can be highly influenced by genetic background. The foreseeable objective is to select personalized therapeutics, based on genetics characteristics that will result in more efficient and less toxic treatment. We review the current data focusing on the BRMs widely used in the practice of dermatology.

Published
2010

7. [Biological therapy for psoriasis: practical experience at a French dermatology unit]

Author

Saccomani, C., Penz, S., Guerre-Schmidt, R., Riou, M.-O., Pelletier, Fabien, Puzenat, E., Mermet, I., Levang, J., Humbert, Philippe, Aubin, François, Université Libre de Bruxelles [Bruxelles] ( ULB ), Département de dermatologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques-Université de Franche-Comté ( UFC ), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC ( HOTE GREFFON ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Université de Franche-Comté ( UFC ), Institut de recherches sur la catalyse et l'environnement de Lyon ( IRCELYON ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique ( CNRS ), Centre Interdisciplinaire de Nanoscience de Marseille ( CINaM ), Aix Marseille Université ( AMU ) -Centre National de la Recherche Scientifique ( CNRS ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Université libre de Bruxelles (ULB), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Institut de recherches sur la catalyse et l'environnement de Lyon (IRCELYON), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC), Centre Interdisciplinaire de Nanoscience de Marseille (CINaM), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC), Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), and Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO)

Subjects
MESH : Immunoglobulin G, MESH : Retrospective Studies, MESH: Treatment Failure, MESH : Psoriasis, MESH : Cohort Studies, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Treatment Outcome, Antibodies, Monoclonal, Humanized, Receptors, Tumor Necrosis Factor, Etanercept, MESH: Antibodies, Monoclonal, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Cohort Studies, MESH : Treatment Failure, Humans, Psoriasis, Treatment Failure, MESH : Safety, MESH : Immunosuppressive Agents, MESH: Cohort Studies, Retrospective Studies, MESH: Treatment Outcome, MESH: Immunoglobulin G, MESH: Psoriasis, MESH: Humans, MESH: Safety, MESH : Humans, Antibodies, Monoclonal, MESH: Retrospective Studies, MESH: Receptors, Tumor Necrosis Factor, Infliximab, MESH : Receptors, Tumor Necrosis Factor, Treatment Outcome, MESH: Dermatologic Agents, MESH : Dermatologic Agents, Immunoglobulin G, MESH : Antibodies, Monoclonal, Dermatologic Agents, MESH: Immunosuppressive Agents, Safety, Immunosuppressive Agents
Abstract

International audience; BACKGROUND: The course of biological therapy (BT) in clinical practice may differ markedly from treatment schedules in clinical trials. Treatment modifications and patient characteristics can affect treatment safety and efficacy. In addition, long-term results concerning the use of BT in clinical practice are lacking. OBJECTIVES: To report our experience of BT in terms of short- and long-term efficacy and safety. PATIENTS AND METHODS: The retrospectively analysed cohort consisted of psoriasis patients receiving BT between 2004 and 2008. Patients in clinical trials were excluded. Mean body surface area (BSA) and Dermatology Life Quality Index were recorded. RESULTS: Fifty-eight patients undergoing 86 courses of BT were enrolled. Thirty-three patients were treated with efalizumab, 21 with infliximab and 32 with etanercept. During the study period, 40% of patients were switched to another BT. The number of patients attaining BSA-75 at 3and 6months respectively was 38% and 75% for efalizumab, 62% and 61% for infliximab, and 36% and 61% for etanercept. After 24months of follow-up, only 33% of patients (34% of patients with efalizumab, 52% with infliximab and 22% with etanercept) were still following their initial BT, with treatment being discontinued in 52% of patients due to adverse events or treatment failure. DISCUSSION: Our study confirms the efficacy and feasibility of BT in clinical practice. However, the high frequency of BT discontinuation for adverse events or non-response led to sequential therapy using different biological treatments.

Published
2009

8. [Botulinum toxin in disabling dermatological diseases]

Author

R, Messikh, L, Atallah, F, Aubin, P, Humbert, Département de dermatologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques-Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC ( HOTE GREFFON ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Université de Franche-Comté ( UFC ), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Saas, Philippe, Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Hôpital Saint-Jacques-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC)

Subjects
Botulinum Toxins, MESH : Neuromuscular Agents, Hidrocystoma, MESH : Psoriasis, MESH : Nails, Malformed, MESH : Hidrocystoma, MESH: Hidradenitis Suppurativa, MESH: Botulinum Toxins, MESH: Vulvar Vestibulitis, MESH : Vulvar Vestibulitis, MESH : Keratoderma, Palmoplantar, Keratoderma, Palmoplantar, MESH : Neurodermatitis, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, MESH : Female, MESH : Pemphigus, Benign Familial, MESH: Treatment Outcome, MESH: Psoriasis, MESH: Sweating, Gustatory, MESH : Leg Ulcer, Leg Ulcer, MESH : Darier Disease, MESH: Paresthesia, MESH : Hidradenitis Suppurativa, Hidradenitis Suppurativa, Treatment Outcome, MESH: Sensation Disorders, MESH : Dermatologic Agents, Neuromuscular Agents, MESH : Botulinum Toxins, Sensation Disorders, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, Fissure in Ano, MESH : Skin Diseases, MESH: Pemphigus, Benign Familial, MESH: Fissure in Ano, MESH : Paresthesia, MESH: Leg Ulcer, MESH : Sweating, Gustatory, Pemphigus, Benign Familial, [SDV.IMM] Life Sciences [q-bio]/Immunology, Sweating, Gustatory, Nails, Malformed, MESH: Skin Diseases, MESH : Treatment Outcome, Skin Diseases, MESH: Keratoderma, Palmoplantar, MESH : Hyperhidrosis, Humans, Hyperhidrosis, Psoriasis, Paresthesia, MESH: Nails, Malformed, MESH: Hyperhidrosis, Neurodermatitis, MESH: Humans, MESH : Humans, MESH: Hidrocystoma, MESH: Darier Disease, MESH: Dermatologic Agents, MESH : Fissure in Ano, MESH : Sensation Disorders, Vulvar Vestibulitis, MESH: Neuromuscular Agents, Dermatologic Agents, Darier Disease, MESH: Female, MESH: Neurodermatitis
Abstract

International audience; Botulinum toxin could represent nowadays a new treatment modality especially for cutaneous conditions in course of which conventional treatments remain unsuccessful. Besides palmar and plantar hyperhidrosis, botulinum toxin has demonstrated efficacy in different conditions associated with hyperhidrosis, such as dyshidrosis, multiple eccrine hidrocystomas, hidradenitis suppurativa, Frey syndrome, but also in different conditions worsened by hyperhidrosis such as Hailey-Hailey disease, Darier disease, inversed psoriasis, aquagenic palmoplantar keratoderma, pachyonychia congenital. Moreover, different cutaneous conditions associated with sensitive disorders and/or neurological involvements could benefit from botulinum toxin, for example anal fissures, leg ulcers, lichen simplex, notalgia paresthetica, vestibulitis. Endly, a case of cutis laxa was described where the patient was improved by cutaneous injections of botulinum toxin.

Published
2009

9. Mécanismes d'action des toxines et neurotoxines botuliques [Mechanisms of action of botulinum toxins and neurotoxins]

Author

Poulain, Bernard, Lonchamp, E., Jover, E., Popoff, Michel R., Molgó, Jordi, Institut des Neurosciences Cellulaires et Intégratives (INCI), Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique (CNRS), Bactéries anaérobies et Toxines, Institut Pasteur [Paris], Institut de Neurobiologie Alfred Fessard (INAF), Centre National de la Recherche Scientifique (CNRS), Laboratoire de neurobiologie cellulaire et moléculaire (NBCM), and Institut Pasteur [Paris] (IP)

Subjects
MESH: Clostridium botulinum, MESH: Humans, MESH: Molecular Sequence Data, cibles intraneuronales des neurotoxines botuliques, membrane receptors of the botulinum neurotoxins], botulinum neurotoxin, MESH: Metalloendopeptidases, intraneuronal targets of the botulinum neurotoxins, MESH: Botulinum Toxins, MESH: Dermatologic Agents, synapse, MESH: Neuromuscular Agents, MESH: Synaptic Transmission, Toxine botulique, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], MESH: Nerve Tissue Proteins, récepteurs membranaires des neurotoxines botuliques [Botulinum toxin, neurotoxine botulique
Abstract

Review; International audience; Les neurotoxines botuliques (BoNTs, 7 sérotypes, A-G) sont des protéines produites par des bactéries du genre Clostridium . Les BoNTs sont associées à des protéines non toxiques et forment un complexe appelé toxine botulique. Les BoNTs inhibent spécifiquement la libération vésiculaire de neurotransmetteur. Leur mécanisme d'action cellulaire comprend plusieurs étapes : après leur liaison via leur chaîne lourde à des récepteurs neuronaux comprenant un ganglioside et une protéine vésiculaire (SV2 pour la BoNT de type A et synaptotagmine pour la BoNT/B), les BoNTs sont internalisées dans les terminaisons nerveuses par endocytose. L'acidification de la vésicule de capture entraîne la translocation de la chaîne légère de BoNT dans le cytoplasme neuronal. La chaîne légère de BoNT est une métalloprotéase à zinc qui, selon le toxinotype, clive l'une ou deux des protéines VAMP/synaptobrévine, SNAP25 ou syntaxine. Comme ces trios protéines interviennent dans le processus de fusion des vésicules synaptiques avec la membrane plasmique, leur clivage provoque l'inhibition de l'exocytose d'acétylcholine. La durée du blocage de la neurotransmission dépend essentiellement de la rémanence de la chaîne légère de la neurotoxine dans les terminaisons nerveuses. La mise en place temporaire de nouvelles terminaisons nerveuses — qui sont rétractées après que la plaque motrice d'origine a retrouvé sa pleine fonctionnalité — peut provoquer une récupération fonctionnelle anticipée. [Several bacteria of the Clostridium genus (C. botulinum) produce 150 kDa di-chainal protein toxins referred as botulinum neurotoxins or BoNTs. They associate with non-toxic companion proteins and form a complex termed botulinum toxin. BoNTs specifically inhibit vesicular neurotransmitter release. The cellular action of BoNTs can be depicted according to a multi-step model : The toxin's heavy chain mediates binding to specific receptors comprised of a ganglioside moiety and a vesicular protein (SV2 for BoNT type A, synaptotagmin for BoNT type B), followed by endocytotic internalisation of the BoNT/receptor complex. Vesicle recycling induces BoNT internalisation. Upon acidification of vesicles, the light chain of the neurotoxin is translocated into the cytosol. Here, this zinc-endopeptidase cleaves one or two among three synaptic proteins (VAMP-synapto-brevin, SNAP25, and syntaxin). As the three protein targets of BoNT play major role in fusion of synaptic vesicles at the release sites, their cleavage is followed by blockade of neurotransmitter exocytosis. Importantly, as the BoNT receptors and intracellular targets are present in all nerve terminals, the BoNTs are not specific for cholinergic transmission. Duration of their inhibitory action is mainly determined by the the life-time of the toxin's light chain in the cytosol. Sprouting of new nerve-endings, which are retracted when the poisoned nerve terminals have recovered full functionality, may lead to anticipated recovery of the poisoned nerve terminals.]

Published
2009

10. Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis

Author

Zhikun Zhang, Mei Li, Pierre Chambon, Pierre Hener, Daniel Metzger, Shigeaki Kato, Institut de génétique et biologie moléculaire et cellulaire (IGBMC), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Louis Pasteur - Strasbourg I, and Université Louis Pasteur - Strasbourg I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Keratinocytes, Receptors, Retinoic Acid, Administration, Topical, Retinoic acid, MESH: Retinoid X Receptor alpha, MESH: Mice, Knockout, Calcitriol receptor, chemistry.chemical_compound, Mice, 0302 clinical medicine, MESH: Animals, Calcipotriol, Cells, Cultured, Retinoid X Receptor beta, Skin, Mice, Knockout, MESH: Cytokines, 0303 health sciences, Multidisciplinary, Vitamins, Biological Sciences, MESH: Keratinocytes, MESH: Administration, Topical, 3. Good health, MESH: Calcium, Cytokines, Female, Retinoid X receptor beta, Dimerization, MESH: Cells, Cultured, medicine.medical_specialty, Thymic stromal lymphopoietin, MESH: Mice, Transgenic, MESH: Receptors, Calcitriol, Mice, Transgenic, Retinoid X receptor, Biology, Dermatitis, Atopic, 03 medical and health sciences, Retinoids, MESH: Skin, Calcitriol, Thymic Stromal Lymphopoietin, MESH: Dermatitis, Atopic, Internal medicine, medicine, Animals, Humans, MESH: Retinoid X Receptor beta, MESH: Retinoids, MESH: Mice, 030304 developmental biology, MESH: Receptors, Retinoic Acid, MESH: Humans, Retinoid X Receptor alpha, Retinoid X receptor alpha, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, body regions, Retinoic acid receptor, MESH: Dermatologic Agents, Endocrinology, MESH: Dimerization, chemistry, MESH: Calcitriol, Cancer research, Receptors, Calcitriol, MESH: Vitamins, Calcium, Dermatologic Agents, MESH: Female, 030215 immunology
Abstract

We have demonstrated that cytokine thymic stromal lymphopoietin (TSLP), whose expression is rapidly induced upon keratinocyte-selective ablation of retinoid X receptors (RXRs) -α and -β in the mouse (RXRαβ ep−/− mice), plays a key role in initiating a skin and systemic atopic dermatitis-like phenotype. We show here that topical application of the physiologically active ligand [1α,25-(OH) 2 D 3 ; calcitriol] of the vitamin D receptor, or of its low-calcemic analog MC903 (calcipotriol; Dovonex), induces TSLP expression in epidermal keratinocytes, which results in an atopic dermatitis-like syndrome mimicking that seen in RXRαβ ep−/− mutants and transgenic mice overexpressing TSLP in keratinocytes. Furthermore, topical application of retinoic acid receptor RARγ-selective agonist BMS961 also induces TSLP expression either on its own or synergistically with 1α,25-(OH) 2 D 3 . Our data demonstrate that RXR/vitamin D receptor and RXR/retinoic acid receptor-γ heterodimers and their ligands cell-autonomously control the expression of TSLP in epidermal keratinocytes of the mouse. We propose molecular mechanisms through which vitamin D3 and retinoic acid signalings could be involved in the pathogenesis of atopic diseases.

Published
2006

11. [Anti-TNF alpha in the treatment of psoriatic arthritis]

Author

Claudepierre , Pascal, Wendling , Daniel, Cohen , Jean-David, Service de rhumatologie [CHU Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Humbert, Murielle, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor, Agents pathogènes et inflammation - UFC (EA 4266) ( API ), and Université de Franche-Comté ( UFC )

Subjects
MESH: Antirheumatic Agents, Time Factors, MESH : Randomized Controlled Trials as Topic, MESH: Risk Assessment, MESH : Multicenter Studies as Topic, Severity of Illness Index, Receptors, Tumor Necrosis Factor, MESH: Antibodies, Monoclonal, Etanercept, MESH: Arthritis, Psoriatic, Multicenter Studies as Topic, MESH : Risk Assessment, MESH : Algorithms, MESH: Treatment Outcome, Randomized Controlled Trials as Topic, MESH : Tumor Necrosis Factor-alpha, MESH: Immunoglobulin G, [SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Antibodies, Monoclonal, MESH : Antirheumatic Agents, MESH : Dermatologic Agents, Treatment Outcome, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, MESH : Antibodies, Monoclonal, Antirheumatic Agents, MESH : Severity of Illness Index, Algorithms, MESH : Time Factors, MESH: Forecasting, MESH : Immunoglobulin G, MESH: Algorithms, MESH : Treatment Outcome, Antibodies, Monoclonal, Humanized, Risk Assessment, [ SDV.MHEP.RSOA ] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, MESH: Severity of Illness Index, Humans, MESH : Forecasting, MESH : Arthritis, Psoriatic, MESH: Humans, Tumor Necrosis Factor-alpha, MESH : Humans, MESH: Time Factors, Arthritis, Psoriatic, Adalimumab, MESH: Receptors, Tumor Necrosis Factor, MESH : Receptors, Tumor Necrosis Factor, Infliximab, MESH: Dermatologic Agents, MESH: Randomized Controlled Trials as Topic, MESH: Tumor Necrosis Factor-alpha, Immunoglobulin G, MESH: Multicenter Studies as Topic, Dermatologic Agents, Forecasting
Abstract

National audience; Psoriatic arthritis is an inflammatory and possibly destructive form of arthritis. As in rheumatoid arthritis and ankylosing spondylitis, the use of biological therapy in psoriatic arthritis is a therapeutic revolution: both articular and cutaneous efficacy have been shown, and some improvement is visible on radiography. The benefit-risk ratio will improve when we learn to identify more accurately the patients likely to benefit from these treatments.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results